Smaller doses for perioral treatment than for upper facial purposes are used because the oral musculature responds much more strongly to precisely the same BTX-A dosing. Only one planning of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole indicator and FDA approval lies in treatments of cervical dystonia. 7. https://botulinum-toxins39516.xzblogs.com/76225151/little-known-facts-about-botulinum-toxins